$CLCS
Cell Source, Inc. Stock $clcs

$clcs Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222030233 Filed on November 02, 2022

Income Statement

Concept	2022 Q4	2022 Q1	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$607.6K	$573.7K	$361.4K
YoY Change	68.1%	-32.52%	-42.06%
% of Gross Profit
Research & Development	$465.2K	$464.5K	$235.8K
YoY Change	97.3%	71.25%	11.28%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.073M	$1.053M	$586.8K
YoY Change	82.82%	-6.13%	-29.79%
Operating Profit		-$1.053M
YoY Change		-6.13%
Interest Expense	-$264.5K	-$239.9K	-$154.8K
YoY Change	70.87%	-40.57%	-64.69%
% of Operating Profit
Other Income/Expense, Net		-$239.9K
YoY Change		-40.53%
Pretax Income	-$1.337M	-$1.293M	-$835.0K
YoY Change	60.15%	-15.23%	-34.46%
Income Tax
% Of Pretax Income
Net Earnings	-$1.625M	-$1.293M	-$835.0K
YoY Change	94.61%	-15.2%	-34.46%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.05
Diluted Earnings Per Share	-$0.05	-$37.57K	-$24.72K
COMMON SHARES
Basic Shares Outstanding	35.25M shares	34.40M shares
Diluted Shares Outstanding		34.40M shares

Balance Sheet

Concept	2022 Q4	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$222.7K	$132.0K	$93.10K
YoY Change	139.17%		-62.02%
Cash & Equivalents	$222.7K	$132.0K	$93.10K
Short-Term Investments
Other Short-Term Assets	$23.01K	$23.57K	$220.7K
YoY Change	-89.57%	-89.07%	6.49%
Inventory
Prepaid Expenses	$164.2K	$121.2K	$203.8K
Receivables
Other Receivables
Total Short-Term Assets	$409.9K	$276.8K	$313.8K
YoY Change	30.62%	28.33%	-30.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change
Total Long-Term Assets	-$5.00	-$1.00	$0.00
YoY Change		-100.0%
TOTAL ASSETS
Total Short-Term Assets	$409.9K	$276.8K	$313.8K
Total Long-Term Assets	-$5.00	-$1.00	$0.00
Total Assets	$409.8K	$276.8K	$313.8K
YoY Change	30.62%	-13.17%	-30.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$680.3K	$332.9K	$223.0K
YoY Change	205.02%	118.37%	15.5%
Accrued Expenses	$1.486M	$918.6K	$3.117M
YoY Change	-52.34%	-67.94%	1.21%
Deferred Revenue
YoY Change
Short-Term Debt	$768.1K	$759.9K	$759.9K
YoY Change	1.08%	-16.77%	-24.98%
Long-Term Debt Due	$1.058M	$762.2K	$1.984M
YoY Change	-46.67%	-83.64%	-44.38%
Total Short-Term Liabilities	$13.04M	$10.27M	$10.14M
YoY Change	28.64%	9.79%	20.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.04M	$10.27M	$10.14M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$13.04M	$10.27M	$10.14M
YoY Change	28.64%	9.79%	20.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.35M	-$32.47M	-$31.18M
YoY Change	16.57%
Common Stock	$36.08K	$34.44K	$34.36K
YoY Change	5.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.63M	-$9.997M	-$9.826M
YoY Change
Total Liabilities & Shareholders Equity	$409.8K	$276.8K	$313.8K
YoY Change	30.62%	-13.17%	-30.63%

Cashflow Statement

Concept	2022 Q4	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$1.625M	-$1.293M	-$835.0K
YoY Change	94.61%	-15.2%	-34.46%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$723.3K	-$1.028M	-$459.2K
YoY Change	57.51%	-7.74%	-39.31%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	880.0K	$1.067M	-47.15K
YoY Change	-1966.38%	9.75%	-104.98%
NET CHANGE
Cash From Operating Activities	-723.3K	-$1.028M	-459.2K
Cash From Investing Activities
Cash From Financing Activities	880.0K	$1.067M	-47.15K
Net Change In Cash	156.7K	$38.90K	-506.4K
YoY Change	-130.95%	-127.39%	-365.97%
FREE CASH FLOW
Cash From Operating Activities	-$723.3K	-$1.028M	-$459.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0379665
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001569340
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q1	CLCS	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty		usd
CY2022Q1	CLCS	Gain On Forgiveness Of Accrued Interest GainOnForgivenessOfAccruedInterest		usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022Q1	CLCS	Gain On Forgiveness Of Accrued Interest GainOnForgivenessOfAccruedInterest		usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense		usd
CY2022Q1	CLCS	Increase Decrease In Accrued Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesRelatedParties		usd
CY2021Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	CLCS	Issuance Of Common Stock Pursuant To Cashless Warrant Exercise IssuanceOfCommonStockPursuantToCashlessWarrantExercise		usd
CY2022Q1	CLCS	Accrued Interest Converted Into Notes Payable AccruedInterestConvertedIntoNotesPayable		usd
CY2021Q1	CLCS	Accrual Of Warrant Obligations In Connection With Issuance Of Notes Payable AccrualOfWarrantObligationsInConnectionWithIssuanceOfNotesPayable		usd
CY2022Q1	CLCS	Issuance Of Warrants In Satisfaction Of Accrued Interest IssuanceOfWarrantsInSatisfactionOfAccruedInterest		usd
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2022Q1	CLCS	Issuance Of Warrants IssuanceOfWarrants		usd
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	000-55413
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Cell Source, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
CY2022Q1	dei	City Area Code CityAreaCode	(646)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	416-7896
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35252389	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131999	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93095	usd
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	121236	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	203750	usd
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	23574	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	16922	usd
CY2022Q1	us-gaap	Assets Assets	276809	usd
CY2021Q4	us-gaap	Assets Assets	313767	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	332859	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	223041	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	918568	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1097021	usd
CY2022Q1	CLCS	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	72000	usd
CY2021Q4	CLCS	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	72000	usd
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	523972	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	532960	usd
CY2022Q1	CLCS	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	882345	usd
CY2021Q4	CLCS	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	649265	usd
CY2022Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	778043	usd
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	766102	usd
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	759912	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	759912	usd
CY2022Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	150000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	150000	usd
CY2022Q1	CLCS	Convertible Notes Payable Current Net ConvertibleNotesPayableCurrentNet	612207	usd
CY2021Q4	CLCS	Convertible Notes Payable Current Net ConvertibleNotesPayableCurrentNet	1834446	usd
CY2022Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4616874	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	3725000	usd
CY2022Q1	CLCS	Advances Payable Current AdvancesPayableCurrent	135000	usd
CY2021Q4	CLCS	Advances Payable Current AdvancesPayableCurrent	135000	usd
CY2022Q1	CLCS	Advances Payable Related Party Current AdvancesPayableRelatedPartyCurrent	100000	usd
CY2021Q4	CLCS	Advances Payable Related Party Current AdvancesPayableRelatedPartyCurrent	100000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27926	usd
CY2022Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	392146	usd
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	67229	usd
CY2022Q1	us-gaap	Liabilities Liabilities	10273926	usd
CY2021Q4	us-gaap	Liabilities Liabilities	10139902	usd
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34437076	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34437076	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34360546	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34360546	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	34437	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	34361	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22437652	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21316318	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32471003	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31178428	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9997117	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	276809	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	313767	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	464505	usd
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	235764	usd
CY2022Q1	CLCS	Research And Development Related Party ResearchAndDevelopmentRelatedParty	14500	usd
CY2021Q1	CLCS	Research And Development Related Party ResearchAndDevelopmentRelatedParty	35475	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	573667	usd
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	850117	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1052672	usd
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	1121356	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1052672	usd
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1121356	usd
CY2022Q1	us-gaap	Interest Expense Other InterestExpenseOther	48412	usd
CY2021Q1	us-gaap	Interest Expense Other InterestExpenseOther	256383	usd
CY2022Q1	CLCS	Interest Expense Related Parties InterestExpenseRelatedParties	118353	usd
CY2021Q1	CLCS	Interest Expense Related Parties InterestExpenseRelatedParties	24504	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	66537	usd
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	122763	usd
CY2022Q1	CLCS	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	6601	usd
CY2021Q1	CLCS	Gain On Forgiveness Of Accrued Interest GainOnForgivenessOfAccruedInterest	49983	usd
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49718	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-239903	usd
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-403385	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1292575	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1524741	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	324917	usd
CY2021Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	223391	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1617492	usd
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1748132	usd
CY2022Q1	CLCS	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.05
CY2021Q1	CLCS	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.05
CY2022Q1	CLCS	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	34400181	shares
CY2021Q1	CLCS	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	32556476	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2022Q1	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	1433095	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-324917	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8043	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	5372	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1292575	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9997117	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-7947382	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-223391	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	196966	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	139728	usd
CY2021Q1	CLCS	Warrants Issued In Satisfaction Of Accrued Interest WarrantsIssuedInSatisfactionOfAccruedInterest	82350	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	206400	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	31276	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-1524741	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-9038794	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1292575	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1524741	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	73138	usd
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	122763	usd
CY2021Q1	CLCS	Gain On Forgiveness Of Accrued Interest GainOnForgivenessOfAccruedInterest	49983	usd
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49718	usd
CY2022Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	33609	usd
CY2021Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	180991	usd
CY2021Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	206400	usd
CY2022Q1	CLCS	Warrants Based Compensation WarrantsBasedCompensation	4960	usd
CY2021Q1	CLCS	Warrants Based Compensation WarrantsBasedCompensation	31372	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-82514	usd
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3907	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	6652	usd
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	12399	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	109818	usd
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-40670	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-178453	usd
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-53903	usd
CY2021Q1	CLCS	Increase Decrease In Accrued Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesRelatedParties	-122500	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-80157	usd
CY2021Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	99174	usd
CY2022Q1	CLCS	Increasedecreaseinaccrued Interest Related Parties IncreasedecreaseinaccruedInterestRelatedParties	213275	usd
CY2021Q1	CLCS	Increasedecreaseinaccrued Interest Related Parties IncreasedecreaseinaccruedInterestRelatedParties	740	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	12353	usd
CY2021Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-5150	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1028170	usd
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1114281	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	95000	usd
CY2021Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1197250	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1000000	usd
CY2021Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	100000	usd
CY2021Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	125000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27926	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1067074	usd
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	972250	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38904	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-142031	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93095	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	245119	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	131999	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103088	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	30515	usd
CY2021Q1	CLCS	Issuance Of Common Stock Pursuant To Cashless Warrant Exercise IssuanceOfCommonStockPursuantToCashlessWarrantExercise	125	usd
CY2021Q1	CLCS	Accrued Interest Converted Into Notes Payable AccruedInterestConvertedIntoNotesPayable	41950	usd
CY2022Q1	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	8043	usd
CY2021Q1	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	196966	usd
CY2022Q1	CLCS	Accrual Of Warrant Obligations In Connection With Issuance Of Notes Payable AccrualOfWarrantObligationsInConnectionWithIssuanceOfNotesPayable	114727	usd
CY2021Q1	CLCS	Issuance Of Warrants In Satisfaction Of Accrued Interest IssuanceOfWarrantsInSatisfactionOfAccruedInterest	82350	usd
CY2022Q1	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-324917	usd
CY2021Q1	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-223391	usd
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1433095	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1293000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1028000	usd
CY2022Q1	CLCS	Working Capital Surplus Deficiency WorkingCapitalSurplusDeficiency	-9997000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32471000	usd
CY2022Q1	us-gaap	Notes Payable NotesPayable	1554912	usd
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39196773	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30278362	shares
CY2022Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.75
CY2021Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.75
CY2021Q4	CLCS	Fair Value Inputs Measured On Recurring Basis Beginning Balance FairValueInputsMeasuredOnRecurringBasisBeginningBalance	463650	usd
CY2022Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	33197	usd
CY2022Q1	CLCS	Accrued Interest Warrant One AccruedInterestWarrantOne	114727	usd
CY2022Q1	CLCS	Fair Value Inputs Measured On Recurring Basis Beginning Balance FairValueInputsMeasuredOnRecurringBasisBeginningBalance	611574	usd
CY2020Q4	CLCS	Fair Value Inputs Measured On Recurring Basis Beginning Balance FairValueInputsMeasuredOnRecurringBasisBeginningBalance	624789	usd
CY2021Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	41704	usd
CY2021Q1	CLCS	Issuance Of Warrants IssuanceOfWarrants	-82350	usd
CY2021Q1	CLCS	Fair Value Inputs Measured On Recurring Basis Beginning Balance FairValueInputsMeasuredOnRecurringBasisBeginningBalance	584143	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	154495	shares
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	154495	shares
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	52528	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	52528	usd
CY2022Q1	us-gaap	Notes Payable NotesPayable	1554912	usd
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.75
CY2022Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	76530	shares
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4960	usd
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	237772	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31276	usd
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2019Q4	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	267680	usd

Files In Submission

Name	View Source	Status
0001493152-22-030233-index-headers.html	Edgar Link	pending
0001493152-22-030233-index.html	Edgar Link	pending
0001493152-22-030233.txt	Edgar Link	pending
0001493152-22-030233-xbrl.zip	Edgar Link	pending
clcs-20220331.xsd	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
clcs-20220331_cal.xml	Edgar Link	unprocessable
clcs-20220331_pre.xml	Edgar Link	unprocessable
clcs-20220331_def.xml	Edgar Link	unprocessable
clcs-20220331_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLCS
Cell Source, Inc. Stock $clcs

2022 Q4 Form 10-Q Financial Statement

#000149315222030233 Filed on November 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS Cell Source, Inc. Stock $clcs

2022 Q4 Form 10-Q Financial Statement

#000149315222030233 Filed on November 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS
Cell Source, Inc. Stock $clcs